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OBJECTIVES We tested the hypothesis that severe alterations in myocardial energy metabolism play an
important role in the pathophysiology of human hibernating myocardium (HHM).
BACKGROUND It is well established that a disturbed myocardial energy metabolism results in impairments of
contractile performance, structure and viability. All of these are important characteristics of
HHM.
METHODS In 16 patients with documented coronary artery disease and impaired left ventricular function,
HHM was preoperatively detected by thallium-201 scintigraphy, radionuclide ventriculog-
raphy and low-dose dobutamine echocardiography. These regions were validated as HHM by
their recovery of contractile function three months following revascularization. During
open-heart surgery, transmural biopsies were removed from the hibernating areas and
analyzed both biochemically and morphologically. These findings were compared to normal
human myocardium. All metabolite contents given were normalized for the degree of fibrosis
(control: 9.8  0.5%; HHM: 28.1  3.0%; p  0.05), providing myocellular contents.
RESULTS In HHM, decreased contents (mol/g wet weight) in adenosine triphosphate (ATP)
(control: 4.17  0.26; HHM: 1.72  0.25; p  0.001), creatine phosphate (5.67  0.70 vs.
0.84  0.13; p  0.001) and creatine (27.6  3.19 vs. 11.2  1.56; p  0.0001) were found,
but contents in lactate (2.22  0.26 vs. 25.38  3.53; p  0.001), purine bases (0.58  0.09
vs. 1.26  0.13; p  0.001) and protons (pH units: 7.199  0.01 vs. 6.59  0.07; p  0.001)
were increased. Levels in adenosine diphosphate, adenosine monophosphate and inorganic
phosphate remained unchanged. Energy depletion in HHM was reflected by decreases in the
free energy of ATP hydrolysis and in energy charge.
CONCLUSIONS These data confirm our hypothesis that HHM is energy-depleted myocardium, exhibiting
signs of chronic reduction in resting blood flow and a downregulation of energy turnover. The
alterations in energy metabolism observed may become operative in triggering and maintain-
ing contractile dysfunction, continuous tissue degeneration and cardiomyocyte loss. (J Am
Coll Cardiol 2002;39:1189–98) © 2002 by the American College of Cardiology Foundation
The term “hibernating myocardium” was coined to describe
a state of persistently impaired left ventricular function due
to a reduced coronary blood flow (but distinct from acute
myocardial stunning), which will be partially or completely
restored following revascularization (1). This definition
implies that myocardial hibernation is defined solely by the
clinical time course and not as a pathologic or pathophysi-
ologic entity. Nowadays, chronic experimental animal prep-
arations are available that exhibit sustained impairment of
regional contractile function due to a persistent coronary
artery stenosis (2–5). However, the validity of these models
is a matter of intense debate, for it is hardly possible to
mimic the chronic situation of human hibernating myocar-
dium (HHM) in any animal model (6). Hence, the situation
of myocardial hibernation thus far can only be unequivocally
investigated by analyzing HHM itself. Recently, we de-
scribed alterations in protein composition and synthesis in
HHM, and we postulated that the basic mechanism in
HHM is an incomplete adaptation to a disturbed myocar-
dial oxygen supply/demand ratio resulting in structural
degeneration (7).
Because HHM occurs in conjunction with coronary
artery disease, it can be assumed that alterations in myocar-
dial energy metabolism play a pivotal role in its pathophys-
iology (8). On the basis of noninvasive measurements of
myocardial blood flow and metabolism, conflicting concepts
were proposed, ranging from a chronically reduced myocar-
dial blood flow at rest (1) to myocardial dysfunction caused
by repetitive episodes of stunning due to limited coronary
reserve (9–11). However, there is evidence that the sophis-
ticated tools employed to noninvasively characterize the
energetics of HHM have their limitations and are inade-
quate for precise absolute determinations of myocardial
energy metabolism (8,12,13). In addition to these uncer-
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tainties arising from noninvasive measurements, the fate of
only one or a very few metabolites or tracers can be
simultaneously analyzed, thereby underrating the complex-
ity of myocardial energy metabolism (14).
Because the most important features of HHM—impaired
contractile performance (14,15), tissue degeneration (16,17)
and occurrence of apoptosis (18,19)—directly depend on
the energy status, a thorough description of myocardial
energy metabolism is not only of theoretical interest but also
has direct clinical relevance. Furthermore, a detailed and
complete analysis will enable important conclusions to be
drawn concerning both severity and chronicity of myocar-
dial ischemia underlying this altered myocardial state. Such
an analysis of HHM employing morphological and bio-
chemical techniques was the aim of our study, testing the
hypothesis that HHM results from severe alterations in
myocardial energy metabolism.
MATERIALS AND METHODS
Patients and study protocol. Sixteen patients with angio-
graphically documented coronary heart disease and a re-
duced left ventricular function resulting in the indication for
coronary bypass surgery were studied (Table 1). The study
population consisted of 16 consecutive patients meeting the
criteria of myocardial hibernation as described in detail in
the following text, recruited within six months. Informed
written consent from each patient for every investigation
and approval of the institutional hospital review board of the
University of Freiburg had been obtained.
The HHM was preoperatively detected using established
clinical methods (see the following text). The time interval
between the preoperative examinations and operative revas-
cularization was 6  2 days. During open-heart surgery,
transmural biopsies were removed from the center of the
myocardial area diagnosed as hibernating. All preoperative
clinical investigations were repeated three months after
revascularization in order to document the extent of func-
tional recovery of these regions after restoration of adequate
perfusion (Table 1), thereby validating the preoperative
diagnosis “hibernating myocardium.”
Clinical methods. To diagnose HHM, established clinical
methods, such as low-dose dobutamine echocardiography,
thallium-201 scintigraphy using a stress-redistribution-
reinjection-protocol, radionuclide ventriculography and cor-
onary angiography including left ventriculography, were
used as described in detail previously (7,20). For the
unequivocal diagnosis of hibernating myocardium, all of the
criteria listed must have been met:
1. Echocardiography. There was improvement of regional
contractile function in at least two adjacent abnormal
segments by a factor 1 during dobutamine infusion (5
and 10 g/kg body weight/min, each over 10 min) in the
baseline study and postoperatively at rest.
2. Thallium-201 scintigraphy. Using a stress-redistribution-
reinjection protocol, hibernating myocardium was con-
sidered if partially reversible or completely reversible
stress defects—quantitatively by an increase in uptake by
15% or more, and qualitatively depending on the degree
of tracer redistribution on the reinjection images—in the
baseline study were devoid of signs of ischemia or
infarction in the postoperative examinations (20). Pre-
operatively, myocardial perfusion was estimated by com-
paring the lowest thallium uptake value in the hibernat-
ing area following reinjection with the database of our
reference population. According to the confidence inter-
val (2 SD) of our center’s reference population, a peak
myocardial thallium uptake of 55% or more indicated
unimpaired perfusion (Table 1).
3. Radionuclide ventriculography. There was postoperative
improvement of the preoperatively impaired regional
ejection fraction by at least 5%.
4. Coronary angiography. There was documentation of an
adequate revascularization using venous and/or internal
mammary artery bypass grafts.
Tissue analysis. TISSUE SAMPLING. From the centers of
the myocardial areas identified as HHM by the different
clinical methods, Tru-cut needle biopsies (transmural cyl-
inders of about 1 mm diameter, weighing 8 to 15 mg) were
removed during open-heart surgery from the beating heart
before establishment of extracorporeal circulation and car-
dioplegic arrest. In all patients, these samples were taken
from the anterior wall, supplied by the left anterior descend-
ing coronary artery. These biopsies were either immediately
shock-frozen in liquid nitrogen for high performance liquid
chromatography (HPLC) and immunohistochemistry or
immersed in 3% glutaraldehyde buffered with 0.1 mol/l
Na-cacodylate (at pH 7.4, 440 osmol/l) for electron micros-
copy. Shock-frozen samples were kept in liquid nitrogen
until further use. Following clinical validation of the myo-
cardial regions as hibernating myocardium (three months
postoperatively), the specific examinations of the biopsies
were started.
Abbreviations and Acronyms
ADP  adenosine diphosphate
AMP  adenosine monophosphate
ANOVA  analysis of variance
ATP  adenosine triphosphate
CABG  coronary artery bypass grafting
CMF  cellular myocardial fraction
CP  creatine phosphate
Cr  creatine
EC  energy charge
HEP  high-energy phosphate
HHM  human hibernating myocardium
HPLC  high performance liquid chromatography.
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Table 1. Clinical Data of the Patients
Patient Data RNV Echo Tl-201
Coro Fibrosis
No. Age AP/Dyspnea
Infarction
Thrombolysis
Global EF Regional EF Regional WMS Index Uptake
ECG Preop Postop 3 mon Preop Postop 3 mon Preop Preop Dobu Postop 3 mon Preop Postop Stenosis (%) Content (%)
1 57 CCS 2   36 60 34 73 4 1 1 40 70 75 19
2 70 NYHA 4   10 49 7 56 4 1.5 1 35 65 100* 22
3 68 CCS 2   37 62 31 64 3.3 1 1 45 80 99 17
4 54 —   38 64 34 69 3.7 1 1 35 70 75 31
5 44 CCS 3/NYHA 4   28 43 30 63 4 1 1 35 60 90 13
6 61 CCS 3   32 65 15 72 3.8 2 1 40 80 95 14
7 61 CCS 4†   34 54 28 70 3.7 1 1 35 75 100* 22
8 60 NYHA 3–4   24 44 28 59 3.5 1.5 1 45 70 90 28
9 72 CCS 2/NYHA 2   40 62 31 62 3.5 1 1 40 65 90 27
10 68 CCS 2   26 44 21 55 3.8 1 1 45 70 90 26
11 59 —   30 46 34 54 4 1 1 40 70 90 15
12 60 CCS 3   22 34 24 45 4 1.8 1.8 40 60 100* 37
13 58 CCS 3/NYHA 3   16 34 21 43 3.7 2 2 35 60 90 36
14 67 NYHA 3   20 32 16 34 4 1.8 2.3 35 60 95 51
15 61 CCS 3/NYHA 3   16 26 22 37 4 2.3 2 40 65 75 43
16 67 NYHA 3–4   14 28 16 34 4 2 2.5 35 70 90 48
*Collateralized vessels. †Unstable angina.
AP  angina; CCS  Canadian Cardiovascular Society; Coro  coronary angiography; Dobu  dobutamine; ECG  electrocardiography, signs of transmural infarction (Q-waves), the hibernating area was in a vessel distribution
different from that of myocardial infarction; Echo  echocardiography; EF  global ejection fraction (%); NYHA  New York Heart Association; Regional EF  regional ejection fraction of hibernating areas (%); Regional WMS Index 
wall motion score index of hibernating areas; RNV  radionuclide ventriculography; Stenosis (%)  diameter reduction of the vessels supplying the hibernating area; Tl-201  thallium-201 scintigraphy, stress-redistribution-reinjection
protocol.
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ANALYSIS OF MYOCARDIAL METABOLITIES. Myocardial
metabolite contents (in brackets [ ] in the following equa-
tions) were determined by HPLC (21,22) and are given in
mol/g wet weight. Considering the error arising from varying
degrees of myocardial fibrosis in control and hibernating
myocardium, total myocardial metabolite contents in both
groups were additionally normalized to the cellular myocardial
fraction (CMF), giving values for myocellular content:
contentCMF
100
100  fibrosis%	

 contenttotal
PARAMETERS OF ENERGY METABOLISM. High-energy
phosphate (HEP) content (P) was calculated: P  [CP
(creatine phosphate)]  2[ATP (adenosine triphosphate)]
 [ADP (adenosine diphosphate)].
Energy charge (EC) and free energy of ATP hydrolysis
(GATP) were determined according to Kammermeier et al.
(23); cytosolic metabolite concentrations were calculated
using the formulas provided by Giesen et al. (24):
GATP GATP
0  R  T  ln
[ATP]
[ADP][Pi]
where GATP
0 stands for the standard free energy of ATP
hydrolysis (30.5 kJmol1), R for the gas constant (8.31
Jmol1K1), T for absolute temperature [Kelvin] and Pi
for inorganic phosphate.
Phosphorylation potential (P  Pot) was calculated
according to Clarke et al. (25):
P  Pot 
ATP	
ADP	  [Pi]
Myocardial pH was estimated using ischemic proton
formation considering myocardial buffering capacity accord-
ing to Dennis et al. (26).
FIBROSIS. The fibrotic content of HHM was determined by
electron microscopy and immunohistochemical labeling of
fibronectin. Three different tissue sections, which were ob-
tained from varying biopsy levels, were evaluated. Fibrosis was
quantified by employing the point-counting method following
stereological principles (7,27). The fibrotic area of the tissue
sample was expressed as % of the total myocardial area.
CONTROL TISSUE. The results obtained in HHM were
compared to left ventricular biopsies from patients under-
going operative correction of atrial septal defects (n  3)
and from donor hearts not used for transplantation (n  4),
representing normal human myocardium.
Statistical analysis. Data are mean values  SE. To
evaluate the clinical data, the Friedman and Dunn test,
analysis of variance (ANOVA) and the Scheffe´ F test, the
paired t test and the Mann-Whitney rank-sum test were
used. Fibrosis and the metabolite contents were analyzed
using ANOVA and Scheffe´ testing. A p value of 0.05 was
considered significant.
RESULTS
Clinical data. ECHOCARDIOGRAPHY. Wall motion score
index of hibernating regions decreased from 3.81  0.1 to
1.43  0.13 during dobutamine infusion in the preoperative
study. The postoperative functional improvement was doc-
umented by a wall motion score index of 1.35  0.12; that
is, the extent of functional recovery was predicted by the
preoperative catecholamine stimulation (preop/postop: p 
0.05, preop Dobu/postop: NS; Table 1).
RADIONUCLIDE VENTRICULOGRAPHY. Regional ejection
fraction of the hibernating areas increased significantly from
24.5  2.0% preoperatively to 55.6  3.4% three months
after revascularization, thereby indicating restoration of
unimpaired regional contractile performance. Global left
ventricular ejection fraction at rest improved from 26.4 
2.3% in the baseline study to 46.7  3.3% postoperatively
(preop/postop: p  0.05; Table 1).
THALLIUM-201 SCINTIGRAPHY. Based on qualitative and
quantitative analysis of the reinjection images, 61 (of a total
of 208 investigated) segments were preoperatively classified
as hibernating myocardium. Three months after revascular-
ization, all of these sectors showed normal tracer uptake and
distribution without signs of ischemia or infarction on the
stress-redistribution-reinjection images. The quantitative
evaluation of thallium-201 uptake values to estimate myo-
cardial perfusion showed a significant increase from 38.8 
3.9% in the hibernating regions preoperatively to 68.1 
6.5% three months after revascularization (p  0.05).
CORONARY ANGIOGRAPHY. The degree of stenosis of the
arteries supplying the hibernating regions varied between
75% and 100%. Operative revascularization was performed
using venous and internal mammary artery bypass grafts
(Table 1).
Tissue analysis. MYOCARDIAL METABOLITE CONTENTS
AND ENERGETIC PARAMETERS. Table 2 provides data for
myocardial metabolite contents, normalized to total tissue as
well as related to the cellular myocardial fraction (CMF)
considering the varying degree of myocardial fibrosis be-
tween both groups. In HHM, total HEP contents were
significantly decreased, essentially owing to reduced levels in
ATP and CP (Fig. 1a). This decrease was accompanied by
an increase in lactate content and the sum of purine bases
(Fig. 1b), mainly caused by an increase in inosine content.
In HHM, creatine (Cr) contents were markedly decreased
(Fig. 1c). Adenosine monophosphate (AMP), ADP and
inorganic phosphate remained virtually unchanged, espe-
cially when normalized to CMF (Fig. 1d).
The energetic parameters calculated from these data are
shown in the lower part of Table 2. In HHM, depressed
ratios of ATP/ADP and CP/Cr were found, and a de-
creased CP/ATP ratio could be observed. Moreover, HHM
exhibited a significant reduction in phosphorylation poten-
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tial, GATP, and EC. Estimated myocardial pH was re-
duced in HHM.
MYOCARDIAL FIBROSIS. In HHM, an increased degree of
fibrosis was observed, which was randomly located in the
endocardial, midmyocardial and epicardial layers (control:
9.8  0.5%; HHM: 28.1  3.01%, p  0.05). This was
accompanied by decreased levels in ATP (Fig. 1a) and an
increased ADP/ATP ratio (Fig. 2b).
DISCUSSION
This study presents directly assessed data on the energetic
status of HHM. Major findings are:
1. HHM is severely energy-depleted myocardium. This
depletion is indicated by its decreased content in ATP
and CP as well as reduced values for GATP, EC and the
phosphorylation potential.
2. In HHM, the lactate content was increased, reflecting
stimulation of anaerobic glycolysis. Impaired myocardial
perfusion is furthermore indicated by the accumulation
of purine bases.
3. In this hypoperfused myocardium, unchanged contents
in ADP, AMP and Pi reflect a downregulation of
myocardial energy turnover.
4. The reduced contents in Cr not only indicate chronic
myocardial ischemia but also contradict superimposed
acute ischemia during surgery and biopsy sampling.
Using myocardial biopsies, the present study shows bio-
chemical (metabolite contents) and morphological (fibrosis)
data from the same hibernating area. By this means,
metabolite contents could be normalized to the cellular
myocardial fraction for the first time. Hence, the influence
of varying degrees of extracellular components on metabo-
lite data was excluded. This was not achieved thus far,
because indirect methods such as positron emission tomog-
raphy, nuclear magnetic resonance spectroscopy and other
diagnostics are not able to distinguish between cellular and
noncellular components of the myocardium (8).
Blood flow reduction underlying HHM. Different con-
cepts were proposed with respect to the alterations in
myocardial blood flow that trigger and maintain myocardial
hibernation; these ranged from chronic and sustained isch-
emia due to reduced coronary blood flow at rest to repeated
episodes of myocardial stunning resulting from limited
coronary reserve at unimpaired resting perfusion
(1,10,28,29). Both acute and chronic ischemia induce char-
acteristic myocardial metabolite patterns. Based on the
present observations, our metabolite data (Table 2) allow us
to draw important conclusions on both the severity and
chronicity of the blood flow reduction underlying HHM.
ABSENCE OF ACUTE ISCHEMIA. Despite an increased con-
tent in lactate and inosine, our data argue against acute
myocardial ischemia in the hibernating regions and do not
favor some element of acute aggravation of hypoperfusion
during open heart surgery for the following reason: acute
myocardial ischemia is characterized by the rapid degrada-
tion of myocardial HEP metabolites. A typical metabolite
pattern for acute myocardial ischemia consists of an in-
creased Cr content (resulting from CP breakdown), in-
creased adenosine, ADP and AMP levels (resulting from
ATP decline) and—the most sensitive marker for acute
myocardial ischemia—an increased content in inorganic
phosphate, resulting from any high-energy adenine nucle-
Table 2. Metabolite Contents
Control Hibernation
p ValueMean SEM Mean SEM
Myocardial content
(mol/g wet wt)
ATP 3.753 0.229 1.243 0.184  0.0001
ADP 0.486 0.089 0.532 0.077 0.7004
AMP 0.121 0.036 0.261 0.051 0.083
CP 5.111 0.624 0.624 0.109  0.0001
Cr 24.888 2.915 8.148 1.235  0.0001
HEP 13.103 0.808 3.643 0.504  0.0001
ADO 0.053 0.017 0.095 0.017 0.1193
INO 0.126 0.050 0.704 0.088  0.0001
HX 0.340 0.039 0.167 0.024  0.0001
 purine bases 0.519 0.078 0.889 0.071 0.0044
Lac 2.000 0.240 17.389 2.313 0.0002
Pi 3.962 0.492 3.296 0.459 0.3792
Myocellular content
(mol/g wet wt CMF)
ATP 4.166 0.259 1.715 0.252  0.0001
ADP 0.541 0.101 0.741 0.102 0.2867
AMP 0.134 0.040 0.356 0.063 0.301
CP 5.673 0.698 0.845 0.134  0.0001
Cr 27.572 3.192 11.162 1.558  0.0001
ATPADPAMP 4.841 0.245 2.788 0.369 0.0028
HEP 14.545 0.917 5.017 0.666  0.0001
ADO 0.059 0.019 0.135 0.024 0.0503
INO 0.140 0.056 1.070 0.185  0.0001
HX 0.378 0.045 0.255 0.052 0.0034
 purine bases 0.577 0.088 1.263 0.126 0.016
Lac 2.217 0.261 25.377 3.526 0.0002
Pi 4.407 0.560 4.699 0.609 0.7622
Parameters of energy
metabolism
ATP/(ADP  Pi) 2.909 0.844 0.960 0.163 0.0083
CP/(Cr  Pi) 0.065 0.017 0.035 0.009 0.0276
CP/ATP 1.385 0.172 0.562 0.075  0.0001
 GATP 55.953 0.892 53.150 0.473 0.0037
EC 0.916 0.019 0.734 0.029 0.0017
ADP/ATP 0.137 0.031 0.469 0.048 0.0013
pH 7.199 0.011 6.592 0.074  0.0001
Metabolite contents are given as total myocardial as well as myocellular contents.
Calculated energetic parameters and estimated myocardial pH in control and
hibernating myocardium are shown. Mean values and the standard error of the mean
(SEM) are also given.
ADO  adenosine; ADP  adenosine diphosphate; AMP  adenosine mono-
phosphate; ATP  adenosine triphosphate; CMF  cellular myocardial fraction;
CP  creatine phosphate; Cr  creatine; EC  energy charge; HEP  high-energy
phosphate; HX  hypoxanthine; INO  inosine; Lac  lactate; Pi  inorganic
phosphate;  purine bases  sum of ADO, INO and HX; GATP  free energy of
ATP hydrolysis (given in kJ/mol). P values are as indicated.
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otide metabolizing reaction (14,15). This was not observed
in HHM, thereby confirming clinical and microscopic
findings showing absence of acute myocardial ischemia.
Nevertheless, superimposed ischemia cannot be entirely
excluded because cardiac surgery represents a stressful con-
dition.
NO EVIDENCE FOR REPETITIVE STUNNING. Similarly, our
data do not support the hypothesis that repeated episodes of
stunning underly the pathophysiology of HHM. Increased
levels in lactate and inosine are not compatible with unim-
paired resting flow after short-term hypoperfusion, which—
owing to the PCr-overshoot—would additionally be char-
acterized by increased (and not decreased) CP levels (30).
SUSTAINED IMPAIRMENT OF RESTING BLOOD FLOW IN
HHM. The increased lactate content observed here supports
the concept that myocardial blood flow is permanently
reduced in HHM: lactate formation is typical of impaired
oxidative phosphorylation in situations of a severe supply-
demand imbalance. This switch to glycolytic ATP forma-
tion can only be seen in states of impaired myocardial
perfusion. When blood flow is slightly or moderately re-
duced, increased myocardial anaerobic glycolytic flux does
not inevitably result in an increased myocardial lactate
content, as myocardial perfusion under these conditions still
suffices to ensure the washout of this end-metabolite of the
Embden-Meyerhof pathway. Hence, an increased lactate
content in HHM not only reflects energy shortage but also
indicates severely impaired myocardial perfusion (31). This
is also supported by the increased myocardial inosine con-
tent. In HHM, reduced levels in Cr are indicative of
sustained and chronic blood flow reductions (32) (Fig. 1).
To characterize the severity and chronicity of blood flow
reduction in HHM, the biochemical findings and clinical
data obtained in our study in summary suggest that HHM
rather results from a chronic, severe and sustained reduction
in myocardial blood flow instead of repetitive stunning at
impaired vasodilator reserve. However, recent clinical and
experimental observations indicate a continuous transition
from repetitive stunning at unimpaired resting blood flow to
chronic hibernation with an impairment of resting perfusion
as long as coronary stenosis exists or even progresses
(6,11,29,33). Hence, the differentiation between “function-
al” and “structural” hibernation (29) arbitrarily distinguishes
Figure 1. Myocardial contents. Myocardial metabolite contents for the cellular myocardial fraction (CMF) reflecting myocellular content are given as
mol/g wet weight. ATP  adenosine triphosphate; CP  creatine phosphate; Cr  creatine; ADP  adenosine diphosphate; AMP  adenosine
monophosphate; Pi  inorganic phosphate. Open bars: controls; black bars: hibernating myocardium. Given are mean values  SEM. *Significant
differences (p values, see Table 2), n.s.  not significant.
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two stages of the same pathophysiologic process. Within
this continuum, however, the selected patients of our study,
exerting structural changes and signs of a decreased myo-
cardial blood flow at rest, may unanimously be classified as
“structurally hibernating.”
Contractile dysfunction. Numerous studies reviewed the
influence of energy metabolism on myocardial contractile
performance (15,34). In addition to reduced myocardial
HEP levels (34), accumulation of metabolites—such as
inorganic phosphate, lactate or protons—were associated
with contractile dysfunction during hypoperfusion
(15,35,36). More recent concepts consider energetic param-
eters like free energy of ATP hydrolysis, EC and phosphor-
ylation potential (37,38) to explain contractile dysfunction
in ischemic myocardium.
For HHM, reduced levels in CP and ATP, a decreased
pH value and an increased lactate content were observed.
Moreover, significant alterations occurred in most of the
parameters associated with impaired contractile perfor-
mance, such as phosphorylation potential (25), EC (23) and
GATP (23,39) (Fig. 2). Myocardial ischemia in HHM
affected both the CP/Cr and the ATP/ADP system, though
the decreased CP/ATP ratio suggests that the CP/Cr
system is especially sensitive to the ischemia-induced dis-
turbances in energy metabolism in HHM. As a conse-
quence, it can be assumed that both energy depletion and
metabolite accumulation contribute to impaired contractile
performance of HHM.
COMPARISON WITH ANIMAL MODELS EXHIBITING SUS-
TAINED CONTRACTILE DYSFUNCTION. Various animal
models with sustained contractile dysfunction resulting
from coronary artery stenoses or myocardial hypoperfusion
were used to elucidate the mechanisms of hibernation.
Short-term hibernating myocardium is energetically char-
acterized by a modest increase in myocardial lactate content,
a recovery of myocardial CP (after an initial decline) and
slightly reduced ATP levels (40–42). In this myocardium
exhibiting impaired contractile performance, GATP is
unchanged (39).
In addition to short-term hibernating myocardium, sev-
eral animal models are characterized by chronic regional
contractile dysfunction due to coronary artery obstruction
(2–5). However, difficulties arise when validating data
derived from these animal preparations, as dysfunctional
myocardium in these studies may not necessarily resemble
myocardial hibernation but may be due to repetitive stun-
ning. This is obvious when flow-function relationships and
biochemical as well as morphologic characteristics are eval-
uated. In this context, the basic definition by Canty and
Fallavollita (6) implies that chronic, but reversible, contrac-
tile dysfunction may occur with and without an impairment
in resting myocardial blood flow, the former representing
myocardial hibernation, the latter myocardial stunning.
However, as both states do rather represent two stages of
one and the same pathophysiologic process than completely
distinct and independent phenomena, their clear-cut differ-
entiation may be of significant scientific importance but
only of minor value in clinical routine.
COMPARISON WITH CLINICAL STUDIES INVESTIGATING
SUSTAINED CONTRACTILE DYSFUNCTION. This differenti-
ation also explains the discrepant findings of a recent study
by Wiggers et al. (43) investigating energy metabolism in
human myocardium with reversible and irreversible contrac-
tile dysfunction: in patients with contractile dysfunction
recovering following surgical revascularization, myocardial
contents in ATP, ADP, AMP and lactate were unaltered in
dysfunctional compared to normally contracting, remote
regions of the same heart. However, myocardial blood flow
was not reduced in this reversibly dysfunctional myocar-
dium, suggesting that these myocardial segments repre-
Figure 2. Energetic parameters related to contractile dysfunction (a) and tissue degeneration (b). Values for energy charge (EC), free energy of adenosine
triphosphate (ATP) hydrolysis (GATP) and estimated pH (a) as well as myocardial fibrosis and the adenosine diphosphate (ADP)/ATP ratio (b) in control
(open bars) and hibernating myocardium (black bars), given as mean  SEM. *Significant differences (analysis of variance, p values, see Table 2).
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sented functional rather than structural hibernation (6,29).
In the myocardial regions exhibiting a reduced blood flow at
rest, a decreased ATP content and increased levels in lactate
were found. However, as these regions did not recover
following revascularization, the criteria for myocardial hi-
bernation were not met.
Our observations are, at first sight, contradictory to those
by Wiggers et al. (43). However, these findings complement
each other with regard to the current model for hibernating
myocardium’s pathophysiology (see preceding text): the
study by Wiggers et al. (43) provides data about the energy
metabolism of dysfunctional but recoverable myocardium at
unimpaired resting blood flow (i.e., functional hibernation);
thus, the more severe energetic deteriorations observed in
our study may instead reflect structural hibernation, as
additionally confirmed by an increased degree of fibrosis.
Tissue degeneration and cell death. Recently, we de-
scribed intracellular degeneration of myocytes in HHM.
Furthermore, the messenger ribonucleic acid contents en-
coding contractile, cytoskeletal and adhesive proteins were
reduced, indicating a diminished synthesis rate of these
intracellular proteins (7).
In numerous studies, Morgan et al. (16,17) elaborated the
direct impact of reduced ischemic energy status on myocar-
dial protein metabolism, affecting both synthesis and break-
down. This principal mechanism may also be operative in
HHM, where energy deprivation severely disturbs the
balance between protein formation and degradation. Both
reduced protein turnover and predominating protein decay
result in cellular atrophy by sequestration of cell particles
into the extracellular space and an initiation of repair
mechanisms with development of replacement fibrosis
(7,27).
Morphological signs of acute ischemic injury are rarely
detected in HHM (7). In contrast, apoptosis may contribute
to the structural disintegration of hibernating myocardium,
although—most probably owing to the rapid removal of
dead cells by macrophages (44)—apoptotic nuclear profiles
were only rarely found in previous studies (7,27). Severe
myocyte loss results in the development of replacement
fibrosis and reduced capacity of functional recovery after
revascularization (45).
Because apoptosis requires energy, mild to moderate
decreases in ATP levels (up to 70%) may determine the fate
of dying cells to undergo apoptotic cell death. If ATP
contents drop to lower values, however, oncotic cell death
occurs (18,19,46,47). Moreover, graded decreases in ATP
levels (between 25% and 70%) or increases in the ADP/
ATP ratio (0.2 or greater) not only play an important role in
maintaining the apoptotic cascade but may also suffice to
initialize programmed cell death by themselves (48–50). As
the levels for ATP in HHM were decreased (by about 60%;
ADP/ATP ratio of 0.4, see Fig. 2b) but not completely
exhausted, our data are in good accordance with both
current hypotheses. Hence, at the energy level observed in
HHM, the apoptotic cascade most probably is initiated and
maintained unless an adequate energy metabolism is re-
stored by revascularization. Otherwise, an increasing loss of
HEPs will result in a switch from apoptotic to oncotic cell
death (18,19,51).
Proposed pathomechanism of myocardial hibernation
and its clinical implications. A limitation in myocardial
blood flow results in a severe disturbance of myocardial
energy metabolism, causing both immediate contractile
dysfunction and initiation of tissue degeneration and apo-
ptosis. Timely revascularization will restore this impairment
in energy metabolism, initiating recovery of contractile
function as well as structural restitution. However, the
longer the duration of energetic deprivation, the more
cardiomyocytes degenerate and undergo apoptotic cell
death, resulting in cellular depletion. At later stages of this
continuous loss of myocardial integrity, an increasing degree
of replacement fibrosis will prevent the complete restoration
of regional contractile performance despite adequate revas-
cularization. To save this highly endangered, deenergized
hibernating myocardium, revascularization should be per-
formed as early as possible to allow its complete recovery
and hence to improve the patient’s prognosis.
Study limitations. BIOPSY SAMPLING AND PATIENT SELEC-
TION. To obtain precise comparisons of energy metabolism
in hibernating and normal myocardium, biopsy sampling
from hibernating and completely normal regions of the
same patient would be ideal. However, these patients are
revascularized by percutaneous coronary interventions rather
than by coronary artery bypass grafting (CABG). As out-
lined in the Methods section, the study population consisted
of a selected group of patients with multivessel disease and
impaired left ventricular function resulting in the indication
for CABG (of the 51 patients screened for the study, only
16 met the strict inclusion criteria). Hence, there is serious
concern whether the myocardial regions, which were sup-
plied by an obstructed coronary artery but without clinical
signs of HHM, might have been useful for serving as
appropriate controls. Therefore, data from HHM regions
were compared to normal human myocardium as described.
Under clinical conditions, myocardial biopsy sampling is
inevitably restricted to very few and very small pieces of
tissue. Hence, we cannot definitely ensure that the biopsies
taken from the centers were representative for the entire
hibernating region, especially as HHM was repeatedly
shown to exert a marked heterogeneity in terms of regional
metabolism, structure and function (52).
ESTIMATION OF MYOCARDIAL BLOOD FLOW. The myocar-
dial blood flow was not measured directly. In HHM, the
perfusion was estimated by comparing the lowest thallium
uptake value in the hibernating area following reinjection
with the database of our reference population.
However, as there was a good correlation of the validated
thallium measurements to the conclusions drawn from the
metabolic data, we feel justified that, in our selected group
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of patients, myocardial hibernation was present in regions
showing a decrease in resting myocardial blood flow.
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